Clindamycin Oral: Dosing, Duration, and Precautions
Clindamycin guidance for severe staphylococcal and streptococcal infections, anthrax, and oral completion therapy after parenteral treatment.
Also searched as
Source reviewed
September 2022
Guide category
Oral drugs
Safety boundary
Prescription medicine information for clinician-guided use.
Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.
Therapeutic action
Lincosamide antibacterial.
Indications
- Severe staphylococcal and/or streptococcal infections such as erysipelas, cellulitis, and pneumonia in betalactam-allergic patients.
- Infections due to methicillin-resistant Staphylococcus aureus.
- Uncomplicated cutaneous anthrax.
- Completion treatment following therapy with parenteral clindamycin.
Forms and strengths
- 150 mg and 300 mg capsules.
Dose
- Child: 10 to 13 mg/kg, maximum 600 mg, 3 times daily.
- Adult: 600 mg 3 times daily.
- 1 to < 6 years and 10 to < 20 kg: 1 capsule of 150 mg 3 times daily.
- 6 to < 9 years and 20 to < 30 kg: 1 capsule of 300 mg 3 times daily.
- 9 to < 13 years and 30 to < 45 kg: 3 capsules of 150 mg 3 times daily.
- >= 13 years and adult, >= 45 kg: 2 capsules of 300 mg 3 times daily.
Duration
- Erysipelas and cellulitis: 7 to 10 days.
- Cutaneous anthrax: 7 to 14 days depending on severity.
- Pneumonia: 10 to 14 days.
Contra-indications, adverse effects, precautions
- Do not administer to patients with allergy to lincosamides or a history of pseudomembranous colitis.
- Reduce dosage in patients with hepatic impairment.
- May cause pseudomembranous colitis, rash, jaundice, and severe allergic reactions. In these cases, stop treatment.
- In the event of pseudomembranous colitis, treat for Clostridium difficile infection with oral metronidazole.
- Pregnancy: no contra-indication.
- Breast-feeding: use only when there is no therapeutic alternative and check infant stools because of the risk of pseudomembranous colitis.
Dosage
| Age | Weight | 150 mg capsule | 300 mg capsule |
|---|---|---|---|
| 1 to < 6 years | 10 to < 20 kg | 1 cap x 3 | - |
| 6 to < 9 years | 20 to < 30 kg | - | 1 cap x 3 |
| 9 to < 13 years | 30 to < 45 kg | 3 cap x 3 | - |
| ≥ 13 years and adult | ≥ 45 kg | - | 2 cap x 3 |
Source
MSF Essential drugs practical guidelines (January 2026)
This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.
Rate this guide
Be the first to rate this guide.
